101 related articles for article (PubMed ID: 2150551)
1. [Refractory vomiting with cisplatin therapy. Prospective study with the serotonin receptor antagonist GR 38032F].
du Bois A; Meerpohl HG; Wilhelm C; Quaas L; Barnickel I; Pfleiderer A
Onkologie; 1990 Oct; 13(5):364-8. PubMed ID: 2150551
[TBL] [Abstract][Full Text] [Related]
2. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE
Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552
[TBL] [Abstract][Full Text] [Related]
3. Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy.
Einhorn LH; Nagy C; Werner K; Finn AL
J Clin Oncol; 1990 Apr; 8(4):731-5. PubMed ID: 2138214
[TBL] [Abstract][Full Text] [Related]
4. GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.
Hesketh PJ; Murphy WK; Lester EP; Gandara DR; Khojasteh A; Tapazoglou E; Sartiano GP; White DR; Werner K; Chubb JM
J Clin Oncol; 1989 Jun; 7(6):700-5. PubMed ID: 2523957
[TBL] [Abstract][Full Text] [Related]
5. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
[TBL] [Abstract][Full Text] [Related]
7. Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
Mitchell PL; Evans BD; Allan SG; Forgeson GV; Mak D; Neave L; Humm G; Langley G; Dickson D; Harvey VJ
N Z Med J; 1992 Mar; 105(929):73-5. PubMed ID: 1532054
[TBL] [Abstract][Full Text] [Related]
8. Ondansetron (GR 38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapy.
Hainsworth JD; Omura GA; Khojasteh A; Bryson JC; Finn AL
Am J Clin Oncol; 1991 Aug; 14(4):336-40. PubMed ID: 1830716
[TBL] [Abstract][Full Text] [Related]
9. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron.
du Bois A; Meerpohl HG; Vach W; Kommoss FG; Fenzl E; Pfleiderer A
Eur J Cancer; 1992; 28(2-3):450-7. PubMed ID: 1534250
[TBL] [Abstract][Full Text] [Related]
10. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
Lancet; 1992 Jul; 340(8811):96-9. PubMed ID: 1352024
[TBL] [Abstract][Full Text] [Related]
11. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
[TBL] [Abstract][Full Text] [Related]
12. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
13. The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy.
Seynaeve C; de Mulder PH; Lane-Allman E; van Liessum PA; Verweij J
Clin Oncol (R Coll Radiol); 1991 Jul; 3(4):199-203. PubMed ID: 1834161
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
Marty M; Pouillart P; Scholl S; Droz JP; Azab M; Brion N; Pujade-Lauraine E; Paule B; Paes D; Bons J
N Engl J Med; 1990 Mar; 322(12):816-21. PubMed ID: 2137902
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes FA; Walters RS; Hortobagyi GN
J Clin Oncol; 1991 Jul; 9(7):1268-74. PubMed ID: 1828499
[TBL] [Abstract][Full Text] [Related]
16. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
[TBL] [Abstract][Full Text] [Related]
17. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Kris MG; Tyson LB; Clark RA; Gralla RJ
Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
Depierre A
Bull Cancer; 1996 Feb; 83(2):147-53. PubMed ID: 8652909
[TBL] [Abstract][Full Text] [Related]
19. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.
Markham A; Sorkin EM
Drugs; 1993 Jun; 45(6):931-952. PubMed ID: 7691500
[TBL] [Abstract][Full Text] [Related]
20. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.
Grunberg SM; Stevenson LL; Russell CA; McDermed JE
J Clin Oncol; 1989 Aug; 7(8):1137-41. PubMed ID: 2526864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
